Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Kendall Jenner addresses long-standing rumor about her sexuality - 2Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- 3Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- 4Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- 5China bans storing cremated remains in empty 'bone ash apartments'
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
- Israeli president concerned over proposed renaming of park
- Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- Merz: 80% of Syrians in Germany should return in three years
- German police 'cleared path for fascists with batons,' protesters say
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
